Lisdexamfetamine Dimesylate: In Attention-Deficit Hyperactivity Disorder in Adults
Abstract
Lisdexamfetamine dimesylate is a long-acting amfetamine prodrug that requires in vivo hydrolysis to gradually release active d-amfetamine. It is approved in the US for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and in children aged 6-12 years. In a study in adult stimulant abusers, oral lisdexamfetamine 50 or 100 mg showed less 'likability' response than immediate-release d-amfetamine 40 mg on the Drug Rating Questionnaire-Subject (DRQS) Liking scale. However, there was no significant difference between lisdexamfetamine 150 mg and d-amfetamine 40 mg. In a randomized, double-blind, phase III trial in adult patients with ADHD, oral lisdexamfetamine 30, 50 or 70 mg/day for 4 weeks caused a significantly greater improvement in ADHD-Rating Scale (ADHD-RS) total score than placebo; significant between-group differences favouring lisdexamfetamine were evident after 1 week. Lisdexamfetamine was generally well tolerated in adult patients with ADHD, with most treatment-emergent adverse events being of mild to moderate severity and consistent with the known effects of psychostimulants.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Study subjects on lisdexamfetamine have been reported to have low scores on drug likability scales, even with intravenous use.
“Study subjects on LDX have been reported to have low scores on drug likability scales, even with intravenous use”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [43]
In that study, lisdexamfetamine 50 mg and 100 mg were similar to placebo on liking, but lisdexamfetamine 150 mg was equivalent to 40 mg dextroamphetamine.
“The 50 mg and 100 mg doses of lisdexamfetamine were similar to placebo; however, the 150 mg dose was equivalent to the 40 mg dose of dextroamphetamine.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [43]
In Weber et al randomized six-step crossover Phase I study in individuals with a history of stimulant abuse, compared with placebo, dextroamphetamine and diethylpropion produced significant differences on the Drug Rating Questionnaire-Subject Liking Scale.
“A randomized, six-step, crossover Phase I study43 in individuals with a history of stimulant abuse using placebo, lisdexamfetamine 50 mg, 100 mg, and 150 mg, immediate-release dextroamphetamine 40 mg, diethylpropion 200 mg, and placebo showed that, compared with placebo, dextroamphetamine and diethylpropion produced significant differences on the Drug Rating Questionnaire-Subject Liking Scale.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [43]
Cites
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259 · see citing works
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · see citing works
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers
Krishnan, S. M., & Stark, J. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x242737 · Cited by 55 · see citing works
Faraone, S. V. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1565 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cornforth, C., Sonuga-Barke, E., & Coghill, D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959827 · Cited by 41 · see citing works
Moen, M. D., & Keam, S. J. (2009) · CNS Drugs · doi:10.2165/11201140-000000000-00000 · Cited by 27 · see citing works
Update on optimal use of lisdexamfetamine in the treatment of ADHD
Madaan, V., Kolli, V., Bestha, D., & Shah, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34092 · Cited by 19 · see citing works
- Authors
- Weber, J., & Siddiqui, M. A. A.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Siddiqui, M. Asif A.
- Venue
- CNS Drugs
- Published
- 2009-05
- Volume
- 23
- Issue
- 5
- Pages
- 419-425
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1981797096
- Cited by
- 13
- References
- 5
- Citations by year
- 2020: 1 · 2018: 1 · 2016: 1 · 2014: 2 · 2013: 3
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Illinois at Urbana-Champaign
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, ADHD treatment, stimulant abuse, drug liking, drug tolerability, psychostimulants, ADHD Rating Scale
- MeSH terms
- Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Dose-Response Relationship, Drug, Drug Evaluation, Female, Humans, Male, Surveys and Questionnaires, Clinical Trials, Phase III as Topic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
